522-2666-2, SAMEA104271492

General

Cell Line

hPSCreg name CHUQi001-A
Cite as:
CHUQi001-A (RRID:CVCL_RL75)
Alternative name(s)
522-2666-2, SAMEA104271492
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
CBRCULi002-A
(19-1035-10)
Donor diseases:
myotonic dystrophy type 1
CBRCULi007-A
(14-0730-1)
Donor diseases:
myotonic dystrophy type 1
CBRCULi004-A
(79-1660-2)
Donor diseases:
myotonic dystrophy type 1
CBRCULi005-A
(91-3158-1)
Donor diseases:
myotonic dystrophy type 1
CBRCULi003-A
(59-0944-2)
Donor diseases:
myotonic dystrophy type 1
CBRCULi018-A
(91-2032-7)
Donor diseases:
myotonic dystrophy type 1
CBRCULi019-A
(19-1741-2)
Donor diseases:
myotonic dystrophy type 1
CBRCULi020-A
(79-1761-15)
Donor diseases:
myotonic dystrophy type 1
CBRCULi015-A
(GM23375-1, GM23375 clone 1)
Donor's gene variants:
DMPK – DM1 protein kinase, DMPK – DM1 protein kinase
Donor diseases:
Congenital Myotonic Dystrophy
ZZUi015-A
(ZZU-iPS-DM1-002)
Donor diseases:
myotonic dystrophy type 1
ZZUi006-A
(ZZU-iPS-DM1-001)
Donor's gene variants:
DMPK
Donor diseases:
Steinert myotonic dystrophy
RGIe057-A
(SI-148)
Donor diseases:
myotonic dystrophy type 1
HADe006-A
(HAD 6)
Donor diseases:
myotonic dystrophy type 1
CENSOi008-A
(FB77R2c3, CENSOi260)
Donor's gene variants:
DMPK, DMPK
Donor diseases:
myotonic dystrophy type 1
RGIe061-A
(SI-153)
Donor diseases:
myotonic dystrophy type 1
CBRCULi012-A
(GM04601 clone 21, GM04601-21)
Donor diseases:
myotonic dystrophy type 1
CBRCULi013-A
(GM04602-2, GM04602 clone 2)
Donor diseases:
myotonic dystrophy type 1
VUBe003-A
(VUB03_DM1)
Donor diseases:
myotonic dystrophy type 1
KCLe014-A
(KCL018_MD1)
Donor diseases:
myotonic dystrophy type 1
VUBe019-A
(VUB19_DM1)
Donor diseases:
Steinert myotonic dystrophy
HADe001-A
(HAD 1)
Donor diseases:
myotonic dystrophy type 1
Last update 18th October 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator CHU de Québec-Université Laval Research Center (CHUQ)
Derivation country Canada

External Databases

BioSamples SAMEA104271492
Cellosaurus CVCL_RL75
Wikidata Q54813330

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: allowed
Commercial use: allowed

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 25-29
Ethnicity caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Stage
adult form of DM1
Synonyms
  • Dystrophia myotonica
  • Steinert disease
  • congenital myotonic dystrophy
  • myotonic dystrophy of Steinert
show more synonyms
Disease associated phenotypes
  • Muscle weakness
  • myotonia
Family history yes
Is the medical history available upon request? yes
Is clinical information available? yes

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA104275575

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? No
a non-profit company? No
a for-profit corporation? No
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? No
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? No
How may genetic information associated with the cell line be accessed? Open Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? Yes
Contact data, institution, or website: Laurie Martineau, CRCHU de Québec, www.ipscquebec.com
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Comité d'éthique de la recherche CHU de Québec-Université Laval
Approval number F9-17292
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Comité d'éthique de la recherche CHU de Québec-Université Laval
Approval number F1-26323
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Life technologies
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
Source cell origin
A fluid that is composed of blood plasma and erythrocytes.
Synonyms
  • portion of blood
  • vertebrate blood
  • whole blood
Age of donor (at collection) 25-29
Collected in 1990

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
RT-PCR
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones morphology
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
NANOG
Yes
SSEA-1
No
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
Score:
Marker Present Absent
mCpG
OCT4
Morphology pictures
CHUQi001-A.tif
Bright field CHUQi001-A
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
SRY-box 17
Yes
alpha fetoprotein
Yes
GATA binding protein 4
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
msh homeobox 1
Yes
GATA binding protein 2
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
paired box 6
Yes
neural cell adhesion molecule 1
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage: 8

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Normal
Passage number: 8
Karyotyping method: Array CGH

Other Genotyping (Cell Line)